Back to top

Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat

Read MoreHide Full Article

Merck KGaA is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.

The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.

The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.

We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: The company’s second-quarter 2018 earnings per American Depositary Receipt (ADR) declined 11.6% year over year to $1.47.

Revenue: The company posted revenues of €3.7 billion ($4.4 billion) in the reported quarter, down a mere 0.5% mainly due to unfavorable currency movement of 4.7%. The Healthcare and Life Science segment continues to drive the company’s organic growth.

Key Stats: The company’s new drugs – Bavencio and Mavenclad – continues to show strong growth with sales of €17 million and €20 million, respectively, in the quarter.

2018 Guidance: For 2018, the company increased its net sales guidance to be in the range of €14.1 billion to €14.6 billion from previous outlook of €14 billion to €14.5 billion. However, the company now expects currency movements to have an unfavourable impact of 3% to 5% on EBIDTA compared to previous 4% to 6%.

Merck KGaA Price and EPS Surprise

 

Merck KGaA Price and EPS Surprise | Merck KGaA Quote

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>




Normally $25 each - click below to receive one report FREE:


More from Zacks Tale of the Tape

You May Like